Will drug company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) succeed in its attempted hostile takeover of rival Mylan (MYL), or will it be Mylan that succeeds in its own hostile takeover bid for Perrigo (PRGO)? If the statistics are anything to go by, the chances are that both attempts will fail.
A study by Credit Suisse indicates that, since 1995, only 38% of hostile takeover bids have proved successful. According to the study, the size of the deal makes no difference to the chances of success, but it does point out that no hostile takeover bid over $10 billion has been successfully completed since Amgen acquired biotechnology company Onyx two years ago.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Mylan is attempting to take over Perrigo in a deal that would be worth over $34 billion. Perrigo’s board opposes the bid, but Mylan plans to convene a shareholders’ meeting to approve it early in the third quarter. At the same time, Teva seeks to take over Mylan in an even larger deal, of over $40 billion, and Mylan’s board opposes this adamantly. Completion of the Teva-Mylan deal is conditional on the Mylan-Perrigo deal not going ahead…
Published by Globes [online], Israel business news – www.globes-online.com
Search Results for: Mylan
Teva Issues New Letter to Mylan NV Confirming Seriousness of Offer to Acquire Mylan
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) issued a new open letter on Monday, signed by both the Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, addressed to Robert More…
Mylan to Teva: Stop Playing Games With Our Company
Mylan reports that Teva Pharmaceutical Industries, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake, but did not clarify which anti-trust rule it violated. Five More…
Mylan’s CEO on Teva “They Are Getting Ready to Go Off the Cliff”
“We just don’t think Teva is the right company” to combine with, “They are getting ready to go off the cliff, ” Mylan NV, CEO Heather Bresch said Friday at a conference in New York City hosted by Sanford More…
Perrigo CEO Will Discuss Deal With Mylan at Right Price
Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price. The rival drugmaker’s present bid is nowhere near there. Perrigo More…
Three Way Takeover Battle- Teva: We Can Close Mylan Deal in 2015
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) CFO Eyal Desheh remains upbeat about Teva’s attempts to buy Mylan N.V. (Nasdaq: MYL). At the same time, Mylan continues to oppose the takeover More…
